Abstract
Background: Pharmacological properties of the currently available P2Y12 receptor antagonists differ significantly and lead to different degrees of platelets inhibition and cardiovascular outcomes.
Methods: We performed a systematic review and meta-analysis of the comparative effects of newer antiplatelet agents versus clopidogrel on major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction (MI), stroke, major bleeding and stent thrombosis, in patients with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI).
Results: We identified 11 prospective randomized studies comparing newer antiplatelets to clopidogrel. The total number of participants included in meta-analysis was 70239. The total number of participants treated with clopidogrel was 34792 while 35447 patients were assigned to newer P2Y12 inhibitors, of which 29.4% received ticagrelor, 35.2% prasugrel and 35.4% were loaded with intravenous cangrelor. Ticagrelor use was associated with significantly reduced MACE, all-cause mortality, myocardial infarction and stent thrombosis and similar rates of stroke and major bleeding compared to clopidogrel in patients with ACS and/or PCI. Prasugrel use was associated with significantly lower rates of MACE, MI and stent thrombosis but significantly high rates of major bleeding and thus no all-cause mortality benefit compared to clopidogrel.
Conclusion: Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel.
Keywords: Clopidogrel, ticagrelol, prasugrel, thienopyridines.
Current Pharmaceutical Design
Title:P2Y12 Receptor Antagonists: Which One to Choose? A Systematic Review and Meta-Analysis
Volume: 22 Issue: 29
Author(s): Alexandros Briasoulis, Tesfaye Telila, Mohan Palla, Gerasimos Siasos and Dimitris Tousoulis
Affiliation:
Keywords: Clopidogrel, ticagrelol, prasugrel, thienopyridines.
Abstract: Background: Pharmacological properties of the currently available P2Y12 receptor antagonists differ significantly and lead to different degrees of platelets inhibition and cardiovascular outcomes.
Methods: We performed a systematic review and meta-analysis of the comparative effects of newer antiplatelet agents versus clopidogrel on major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction (MI), stroke, major bleeding and stent thrombosis, in patients with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI).
Results: We identified 11 prospective randomized studies comparing newer antiplatelets to clopidogrel. The total number of participants included in meta-analysis was 70239. The total number of participants treated with clopidogrel was 34792 while 35447 patients were assigned to newer P2Y12 inhibitors, of which 29.4% received ticagrelor, 35.2% prasugrel and 35.4% were loaded with intravenous cangrelor. Ticagrelor use was associated with significantly reduced MACE, all-cause mortality, myocardial infarction and stent thrombosis and similar rates of stroke and major bleeding compared to clopidogrel in patients with ACS and/or PCI. Prasugrel use was associated with significantly lower rates of MACE, MI and stent thrombosis but significantly high rates of major bleeding and thus no all-cause mortality benefit compared to clopidogrel.
Conclusion: Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel.
Export Options
About this article
Cite this article as:
Briasoulis Alexandros, Telila Tesfaye, Palla Mohan, Siasos Gerasimos and Tousoulis Dimitris, P2Y12 Receptor Antagonists: Which One to Choose? A Systematic Review and Meta-Analysis, Current Pharmaceutical Design 2016; 22 (29) . https://dx.doi.org/10.2174/1381612822666160608114424
DOI https://dx.doi.org/10.2174/1381612822666160608114424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Articular Bleeding in Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Risk Factors for Development of Heart Failure
Current Cardiology Reviews Age and Dietary Vitamin C Intake Affect Brain Physiology in Genetically Modified Mice Expressing Human Lipoprotein(A) and Unable to Synthesize Vitamin C
Current Aging Science The Effect of Lead Exposure on Selected Blood Inflammatory Biomarkers in Guinea pigs
Cardiovascular & Hematological Disorders-Drug Targets Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function
Protein & Peptide Letters Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Molecular Basis of Adrenomedullin 1 Receptor Function and Its Roles in the Cardiovascular System
Current Hypertension Reviews Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Cardiovascular & Hematological Agents in Medicinal Chemistry Determination of Bioactive Constituents in Traditional Chinese Medicines by CE with Electrochemical Detection
Current Medicinal Chemistry Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events
Cardiovascular & Hematological Agents in Medicinal Chemistry Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview
Cardiovascular & Hematological Disorders-Drug Targets An Updated Meta-Analysis of the Efficacy and Safety of Acupuncture Treatment for Vascular Cognitive Impairment Without Dementia
Current Neurovascular Research Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets